Fevipiprant

Fevipiprant (INN; code name QAW039) is a drug of the piprant class that was being developed by Novartis. It is a selective, orally available antagonist of the prostaglandin D₂ receptor 2 (DP₂ or CRTh2).^[1][2][3]

Fevipiprant

Clinical data
Routes of administration	Oral
ATC code	none
Legal status
Legal status	Investigational
Pharmacokinetic data
Bioavailability	Unaffected by food[1]
Metabolism	Hepatic glucuronidation
Elimination half-life	~20 hours
Excretion	Renal (≤30%)
Identifiers
IUPAC name {2-methyl-1-[4-(methylsulfonyl)-2-(trifluoromethyl)benzyl]-1H-pyrrolo[2,3-b]pyridin-3-yl}acetic acid
CAS Number	872365-14-5
PubChem CID	23582412
ChemSpider	23582412
UNII	2PEX5N7DQ4
KEGG	D10631
CompTox Dashboard (EPA)	DTXSID501336031
ECHA InfoCard	100.243.911
Chemical and physical data
Formula	C19H17F3N2O4S
Molar mass	426.41 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C2=C(N1CC3=C(C=C(C=C3)S(=O)(=O)C)C(F)(F)F)N=CC=C2)CC(=O)O
InChI InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26) Key:GFPPXZDRVCSVNR-UHFFFAOYSA-N

By 2016 it had advanced to phase III^[4] clinical trials for the treatment of asthma.^[5] However, in 2019 Novartis announced that it was removing fevipiprant from its development program, given that the medicine has failed in two clinical trials in patients with moderate-to-severe asthma. The firm said that it had hoped fevipiprant would be a billion-dollar-selling asthma drug.^[6]

A 2021 analysis sponsored by Novartis of the two phase III trials of fevipiprant concluded that "The ZEAL studies did not demonstrate significant improvement in lung function or other clinical outcomes. These results suggest that DP2 receptor inhibition with fevipiprant is not effective in the studied patient population".^[7]

See also

• Grapiprant
• Setipiprant